Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Perseris

    - PMLiVE

    Alkermes’ new antipsychotic clears FDA advisory committee hurdle

    Target action date for FDA decision is due on 15 November

    - PMLiVE

    Troubled Alkermes eyes November OK for new antipsychotic

    Review begins for potential schizophrenia and bipolar I disorder drug

    - PMLiVE

    Intra-Cellular soars on FDA approval of schizophrenia drug

    Shares rocketed following the announcement

    - PMLiVE

    As the opioid crisis grabs the headlines, the search for safe treatments continues

    Indivior’s Gilles Picard charts a path to greater patient access and new therapies

    - PMLiVE

    Karuna’s shares spike on schizophrenia drug data

    Value leaps to more than $1bn following mid-stage trial results

    - PMLiVE

    Reckitt hammered by $1.4bn opioid settlement bill

    Case centres on Subaxone marketing practices

    - PMLiVE

    Indivior push to diversify boosted by schizophrenia drug approval

    Perseris will face competition from Lundbeck/Otsuka’s Abilify Maintena and J&J’s Invega Sustenna

    Biogen Idec building

    Biogen pays $590m for Pfizer cognition drug

    Early stage studies look positive for schizophrenia drug

    Takeda explores the potential of ‘digital biomarkers’

    Collaborates with Mindstrong Health on mental health research

    - PMLiVE

    Boehringer abandons PDE-targeted Alzheimer’s drug

    But will keep testing the candidate in schizophrenia

    Boehringer Ingelheim headquarters

    Boehringer adds to pipeline again with €628m Autifony CNS deal

    Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia

    - PMLiVE

    FDA panel backs Indivior’s drug to fight opioid addiction

    The former RB pharma unit hopes for sales in the $1bn region

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links